|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...979899100101102103104105106107...156157» |
- Trial primary completion date: Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home (clinicaltrials.gov) - May 3, 2014
P=N/A, N=75, Active, not recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Jan 2014 --> Dec 2014
- Trial completion date: Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home (clinicaltrials.gov) - May 3, 2014
P=N/A, N=75, Active, not recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Jan 2014 --> Dec 2014 Trial completion date: Jan 2014 --> Dec 2014
- Enrollment change, HEOR: The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes (clinicaltrials.gov) - May 3, 2014
P=N/A, N=30, Completed, Sponsor: Rabin Medical Center
Trial completion date: Jan 2014 --> Dec 2014 N=40 --> 30
- Enrollment closed: Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home (clinicaltrials.gov) - May 3, 2014
P=N/A, N=75, Active, not recruiting, Sponsor: Rabin Medical Center
N=40 --> 30 Recruiting --> Active, not recruiting
- Enrollment closed: Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients With Type 1 Diabetes (clinicaltrials.gov) - May 3, 2014
P1, N=25, Active, not recruiting, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- Trial completion, HEOR: The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes (clinicaltrials.gov) - May 3, 2014
P=N/A, N=30, Completed, Sponsor: Rabin Medical Center
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial primary completion date: Overnight MD-Logic (clinicaltrials.gov) - May 3, 2014
P=N/A, N=223, Recruiting, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2015
- Trial completion date: Overnight MD-Logic (clinicaltrials.gov) - May 3, 2014
P=N/A, N=223, Recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Dec 2013 --> Dec 2015 Trial completion date: Dec 2013 --> Dec 2015
- Enrollment change: Overnight MD-Logic (clinicaltrials.gov) - May 3, 2014
P=N/A, N=223, Recruiting, Sponsor: Rabin Medical Center
Trial completion date: Dec 2013 --> Dec 2015 N=118 --> 223
- Trial primary completion date: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis (clinicaltrials.gov) - May 2, 2014
P=N/A, N=34, Completed, Sponsor: Bert Op't Eijnde
N=118 --> 223 Trial primary completion date: Aug 2013 --> Mar 2014
- Trial completion date: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis (clinicaltrials.gov) - May 2, 2014
P=N/A, N=34, Completed, Sponsor: Bert Op't Eijnde
Trial primary completion date: Aug 2013 --> Mar 2014 Trial completion date: Nov 2013 --> Mar 2014
- Trial completion: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis (clinicaltrials.gov) - May 2, 2014
P=N/A, N=34, Completed, Sponsor: Bert Op't Eijnde
Trial completion date: Nov 2013 --> Mar 2014 Active, not recruiting --> Completed
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Trial initiation date: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - May 1, 2014
P3, N=425, Ongoing, Sponsor: Amgen Inc.
Active, not recruiting --> Completed Initiation date: Feb 2014 --> Feb 2014
- Trial primary completion date: Differential Diagnosis of STA-PSV in Thyrotoxicosis (clinicaltrials.gov) - May 1, 2014
P=N/A, N=169, Completed, Sponsor: xiaolong zhao
Initiation date: Feb 2014 --> Feb 2014 Trial primary completion date: Apr 2014 --> Nov 2011
- ||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial completion date: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - May 1, 2014
P3, N=500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2014 --> Nov 2011 Trial completion date: Aug 2015 --> Oct 2015
- Trial completion date: Differential Diagnosis of STA-PSV in Thyrotoxicosis (clinicaltrials.gov) - May 1, 2014
P=N/A, N=169, Completed, Sponsor: xiaolong zhao
Trial completion date: Aug 2015 --> Oct 2015 Trial completion date: Apr 2014 --> Nov 2011
- Enrollment closed: Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes (clinicaltrials.gov) - May 1, 2014
P=N/A, N=36, Active, not recruiting, Sponsor: Sue Brown
Trial completion date: Apr 2014 --> Nov 2011 Recruiting --> Active, not recruiting
- Trial completion: Differential Diagnosis of STA-PSV in Thyrotoxicosis (clinicaltrials.gov) - May 1, 2014
P=N/A, N=169, Completed, Sponsor: xiaolong zhao
Recruiting --> Active, not recruiting Recruiting --> Completed
- Clinical: APCam09: Automated Closed-loop in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=12, Recruiting, Sponsor: University of Cambridge
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 29, 2014
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Recruiting --> Completed Trial primary completion date: Apr 2015 --> May 2015
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 29, 2014
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Trial primary completion date: Apr 2015 --> May 2015 Trial completion date: Apr 2015 --> May 2015
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days (clinicaltrials.gov) - Apr 29, 2014
P2a, N=75, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: Apr 2015 --> May 2015 Trial primary completion date: Mar 2014 --> Apr 2014
- tabalumab (LY2127399) / Eli Lilly
Trial completion date: A Study of Japanese Rheumatoid Arthritis Participants (clinicaltrials.gov) - Apr 29, 2014
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Mar 2014 --> Apr 2014 Trial completion date: Jun 2014 --> Mar 2014
- |||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days (clinicaltrials.gov) - Apr 29, 2014
P2a, N=75, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2014 --> Mar 2014 Active, not recruiting --> Completed
- Enrollment closed: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) - Apr 29, 2014
P1, N=10, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | tabalumab (LY2127399) / Eli Lilly
Trial completion: A Study of Japanese Rheumatoid Arthritis Participants (clinicaltrials.gov) - Apr 29, 2014
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Symlin (pramlintide) / AstraZeneca
Trial termination: Pramlintide Combined With Model Predictive Control Algorithm (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=2, Terminated, Sponsor: University of Virginia
Active, not recruiting --> Completed Recruiting --> Terminated; Modified study; created new study as a result of these modifications
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Pramlintide Combined With Model Predictive Control Algorithm (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=2, Terminated, Sponsor: University of Virginia
Recruiting --> Terminated; Modified study; created new study as a result of these modifications N=18 --> 2
- insulin peglispro (LY2605541) / Eli Lilly
Enrollment open: A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue (clinicaltrials.gov) - Apr 29, 2014
P1, N=24, Recruiting, Sponsor: Eli Lilly and Company
N=18 --> 2 Not yet recruiting --> Recruiting
- Enrollment closed: Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes (Italy) (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=12, Active, not recruiting, Sponsor: University of Virginia
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion, HEOR: MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=23, Completed, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial withdrawal: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Apr 28, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- | Trial termination: A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement (clinicaltrials.gov) - Apr 28, 2014
P4, N=184, Terminated, Sponsor: DePuy International
Not yet recruiting --> Withdrawn Active, not recruiting --> Terminated; DePuy discontinued this product in 2013, the clinical program was reviewed and this Study was closed.
- Trial initiation date: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Apr 28, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; DePuy discontinued this product in 2013, the clinical program was reviewed and this Study was closed. Initiation date: Dec 2013 --> Jun 2014
- Enrollment change: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Apr 28, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2013 --> Jun 2014 N=132 --> 0
- | olendalizumab (ALXN1007) / AstraZeneca
New P2a trial: Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome (clinicaltrials.gov) - Apr 28, 2014
P2a, N=20, Recruiting, Sponsor: Alexion Pharmaceuticals
- Clinical: The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Apr 28, 2014
P=N/A, N=110, Recruiting, Sponsor: Ottawa Hospital Research Institute
- Januvia (sitagliptin) / Merck (MSD)
New P2 trial: EXTYPE-1: Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Apr 27, 2014
P2, N=24, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- | Victoza (liraglutide) / Novo Nordisk
Enrollment closed: ADJUNCT ONE: The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (clinicaltrials.gov) - Apr 27, 2014
P3, N=1404, Active, not recruiting, Sponsor: Novo Nordisk A/S
N=132 --> 0 Recruiting --> Active, not recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P1/2 trial: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Apr 26, 2014
P1/2, N=4, Not yet recruiting, Sponsor: James Chodosh, MD, MPH
- Clinical: Total Knee Replacement With the ROCC Knee (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=500, Completed, Sponsor: Bercovy, Michel, M.D.
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: TOLERATE: Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (clinicaltrials.gov) - Apr 24, 2014
P4, N=230, Not yet recruiting, Sponsor: Biogen Idec
- |||||| Benlysta (belimumab) / GSK
New P2b trial: A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (clinicaltrials.gov) - Apr 24, 2014
P2b, N=118, Not yet recruiting, Sponsor: GlaxoSmithKline
- Clinical: Pilot Tape Harvesting Study (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: Biogen Idec
- Biomarker, Trial completion: HAP-E: Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=87, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Clinical: Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis (IMPACTAR) (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=10000, Enrolling by invitation, Sponsor: Iniciativa Mexicana de Pacientes con Osteoartritis y Artritis Reumatoide
- Enrollment change, Adverse events: Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis (clinicaltrials.gov) - Apr 23, 2014
P1/2, N=22, Completed, Sponsor: Royan Institute
Recruiting --> Completed N=30 --> 22
- |||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open, Combination therapy, Monotherapy: A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs. (clinicaltrials.gov) - Apr 23, 2014
P3, N=300, Recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 22 Not yet recruiting --> Recruiting
- Trial completion, Adverse events: Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis (clinicaltrials.gov) - Apr 23, 2014
P1/2, N=22, Completed, Sponsor: Royan Institute
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial termination: Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=15, Terminated, Sponsor: University of Virginia
Recruiting --> Completed Recruiting --> Terminated; study team will review the collected data and make any necessary changes to the educational tool.